VivoSeq
Oncology

Solid Tumor Cancers

1

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

Solid Tumor Cancers is an early-stage landscape with 1 program across 5 companies. The most active players are Apmonia Therapeutics, Sanofi, Calando Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Apmonia Therapeutics

1 program

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalC

Calando Pharmaceuticals

0 programs

PreclinicalE

Euclises Pharmaceuticals, Inc.

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Tax2

Apmonia Therapeutics

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

9

clinical trials

Completed3 · 33%
Recruiting3 · 33%
Terminated1 · 11%
Unknown status1 · 11%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Study of PAT in Patients With Solid Tumor Cancers
Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT05338658·21 enrolled
A Study of Avutometinib for People With Solid Tumor Cancers
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06104488·23 enrolled
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05638295·105 enrolled
A Phase 1/2a, First-in-human, Open-label, Dose-escalating Study With a Safety Expansion Cohort to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours
Not yet recruiting·AApmonia Therapeutics·Preclinical·NCT07688148·48 enrolled
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
Completed·Sanofi logoSanofi·Phase 1·NCT01436565·26 enrolled
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
Completed·National Cancer Institute (NCI)·Phase 1·NCT00678132·23 enrolled
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212
Completed·GSK logoGSK·Phase 1·NCT01658553·60 enrolled
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Terminated·CCalando Pharmaceuticals·Phase 1·NCT00689065·24 enrolled
ECP-1014 Treatment for Patients With Solid Tumor Cancers
Unknown status·EEuclises Pharmaceuticals, Inc.·Phase 1·NCT04930354·29 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)